Drugs / Tenofovir Exalidex
Tenofovir Exalidex
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03284164 | Sep 2017 → Jan 2018 | impaired renal function disease | ContraVir Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03279146 | Sep 2017 → Jun 2018 | — | ContraVir Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02585440 | Apr → Aug 2016 | infectious disease | ContraVir Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01080820 | Jun → Dec 2010 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02710604 Comparator | May 2016 → Jul 2017 | infectious disease | ContraVir Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir Exalidex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03284164 ↗ |
| Known as | CMX157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02585440 ↗ |
| Known as | Hdp-tenofovir | ChEMBL registry synonym — accepted as the source's own label CHEMBL515564 ↗ |
| Known as | Hexadecyloxypropyl tenofovir | ChEMBL registry synonym — accepted as the source's own label CHEMBL515564 ↗ |
| Known as | TXL | “Tenofovir Exalidex (TXL)” NCT03284164 ↗1“Tenofovir exalidex (TXL)” NCT03279146 ↗ |
| Modality | Other / unclassified | “lipid conjugate TFV(tenofovir)” NCT02710604 ↗ |
| Route | Oral | “One single oral dose of CMX157 will be administered” NCT01080820 ↗ |